US 12,087,405 B2
Methods of processing a biofluid sample
John E. Blume, Bellingham, WA (US); William C. Manning, Redwood City, CA (US); Gregory Troiano, San Mateo, CA (US); Asim Siddiqui, San Francisco, CA (US); Philip Ma, San Jose, CA (US); and Omid C. Farokhzad, Waban, MA (US)
Assigned to PrognomIQ, Inc., San Mateo, CA (US)
Filed by PrognomIQ, Inc., San Mateo, CA (US)
Filed on Apr. 13, 2022, as Appl. No. 17/720,197.
Application 17/720,197 is a continuation of application No. PCT/US2021/015339, filed on Jan. 27, 2021.
Claims priority of provisional application 62/967,995, filed on Jan. 30, 2020.
Prior Publication US 2022/0334118 A1, Oct. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/543 (2006.01); G01N 33/552 (2006.01); G01N 33/574 (2006.01); G16B 40/10 (2019.01); G16H 10/40 (2018.01); G16H 50/70 (2018.01); G01N 30/86 (2006.01)
CPC G16B 40/10 (2019.02) [G01N 33/54326 (2013.01); G01N 33/54346 (2013.01); G01N 33/552 (2013.01); G01N 33/57423 (2013.01); G16H 10/40 (2018.01); G16H 50/70 (2018.01); G01N 30/8686 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A method, comprising: contacting a biofluid sample from a subject suspected of having a non-small cell lung cancer (NSCLC) or a comorbidity of NSCLC with particles to form biomolecule coronas comprising proteins of the biofluid adsorbed to the particles, wherein the proteins comprise one or more of serine protease HTRA1 (HTRA1), peroxidasin homolog (PXDN), anthrax toxin receptor 2 (ANTR2), versican core protein (CSPG2), anthrax toxin receptor 1 (ANTR1), palmitoleoyl-protein carboxylesterase NOTUM (NOTUM), cartilage intermediate layer protein 1 (CILP1), neural cell adhesion molecule 1 (NCAM1), 60S acidic ribosomal protein P2 (RLA2), protein S100-A8 (S10A8), protein S100-A9 (S10A9), tubulin alpha-1 A chain (TBA1 A), and calpain-2 catalytic subunit (CAN2);
obtaining a data set by identifying and measuring the proteins of the biomolecule coronas;
inputting the data set into a classifier that distinguishes between the NSCLC and the comorbidity of NSCLC;
identifying the data set as indicative of the NSCLC or the comorbidity of NSCLC through the classifier; and
administering a cancer treatment to the subject, the cancer treatment comprising an anti-cancer agent, radiation, or cancer resection surgery.